Drugs / C402-CD19-CAR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06830031 | Mar 2025 → Mar 2026 overdue | diffuse large B-cell lymphoma, high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement | Shanghai Exuma Biotechnology Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C402-CD19-CAR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06830031 ↗ |
| Modality | Cell therapy | “C402-CD19-CAR, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy” NCT06830031 ↗ |
| Route | Subcutaneous | “via subcutaneous injection” NCT06830031 ↗ |
| Target | CD19 | “Therapy Targeting CD19” NCT06830031 ↗ |